Literature DB >> 34761355

Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?

Mojca Jensterle1,2, Nika Aleksandra Kravos1,2, Vita Dolžan3, Katja Goričar3, Rok Herman1,2, Manfredi Rizzo4, Andrej Janež5,6.   

Abstract

PURPOSE: Metformin induces GLUT-4 mRNA expression in insulin target tissues in PCOS. It is unclear how long this impact is sustained after withdrawal of metformin. We aimed to compare the effect of metformin withdrawal on GLUT-4 mRNA expression in subcutaneous adipose tissue after prior short (ST, 1 year, N = 11) and long term (LT, at least 3 years, N = 13) treatment in obese PCOS women.
METHODS: At baseline and 6 months after withdrawal, biopsy of subcutaneous adipose tissue followed by quantitative PCR analysis was performed to determine GLUT-4 mRNA expression.
RESULTS: We found no time/effect differences in GLUT-4 mRNA expression in ST (2-dCt at baseline 0.42 (0.16-0.48) vs 2-dCt after 6 months 0.31 (0.22-0.56), p = 0.594) and no time/effect difference in LT group (2-dCt at baseline 0.24 (0.14-0.39) vs 2-dCt after 6 months 0.25 (0.20-0.38), p = 0.382). There was also no difference in GLUT-4 mRNA expression between both groups at baseline and after 6 months.
CONCLUSIONS: In summary, 6 months after metformin withdrawal, GLUT-4 mRNA expression in subcutaneous adipose tissue remained stable, regardless of the prior treatment duration.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adipose tissue; GLUT-4 mRNA; Metformin; PCOS

Mesh:

Substances:

Year:  2021        PMID: 34761355     DOI: 10.1007/s12020-021-02934-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  52 in total

1.  Adipocyte expression of glucose transporter 1 and 4 in PCOS: Relationship to insulin-mediated and non-insulin-mediated whole-body glucose uptake.

Authors:  Uche Ezeh; Ida Y-D Chen; Yen-Hao Chen; Ricardo Azziz
Journal:  Clin Endocrinol (Oxf)       Date:  2019-02-14       Impact factor: 3.478

2.  The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial.

Authors:  J Lord; R Thomas; B Fox; U Acharya; T Wilkin
Journal:  BJOG       Date:  2006-07       Impact factor: 6.531

3.  Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.

Authors:  Catherine Marin DeUgarte; Alfred A Bartolucci; Ricardo Azziz
Journal:  Fertil Steril       Date:  2005-05       Impact factor: 7.329

Review 4.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

5.  Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.

Authors:  A Corbould
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

6.  Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance.

Authors:  Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

7.  Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2.

Authors:  Assel Biyasheva; Richard S Legro; Andrea Dunaif; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

Review 8.  Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.

Authors:  Richard S Legro; V Daniel Castracane; Robert P Kauffman
Journal:  Obstet Gynecol Surv       Date:  2004-02       Impact factor: 2.347

9.  Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Ricardo Azziz; Frank Z Stanczyk; George Sopko; Glenn D Braunstein; Sheryl F Kelsey; Kevin E Kip; Rhonda M Cooper-Dehoff; B Delia Johnson; Viola Vaccarino; Steven E Reis; Vera Bittner; T Keta Hodgson; William Rogers; Carl J Pepine
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

10.  miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance.

Authors:  Yen-Hao Chen; Saleh Heneidi; Jung-Min Lee; Lawrence C Layman; David W Stepp; Gloria Mabel Gamboa; Bo-Shiun Chen; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Diabetes       Date:  2013-03-14       Impact factor: 9.461

View more
  1 in total

Review 1.  Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.

Authors:  Rok Herman; Nika Aleksandra Kravos; Mojca Jensterle; Andrej Janež; Vita Dolžan
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.